Tumor News and Research

RSS

Oncos Therapeutics commences clinical study with oncolytic viruses

Oncos Therapeutics today announced the successful initiation of its Phase I clinical study of CGTG-102, an oncolytic adenovirus suggested as a potential new treatment for many types of solid tumors.

29 May 2012

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Abbott scientists and independent researchers will highlight the latest investigational research findings on HUMIRA (adalimumab) at the European League Against Rheumatism (EULAR) Congress in Berlin, Germany, from 6-9 June, 2012.

29 May 2012

Bioengineers develop first structure to grow small human blood vessels

Mice and monkeys don't develop diseases in the same way that humans do. Nevertheless, after medical researchers have studied human cells in a Petri dish, they have little choice but to move on to study mice and primates. University of Washington bioengineers have developed the first structure to grow small human blood vessels, creating a 3-D test bed that offers a better way to study disease, test drugs and perhaps someday grow human tissues for transplant.

29 May 2012

Blocking Skp2 protein might inhibit glycolysis and treat breast cancer

HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in the May 25 issue of Cell.

28 May 2012

Scientists show how hemizygous deletion can contribute to cancer

Chromosomal deletions in DNA often involve just one of two gene copies inherited from either parent. But scientists haven't known how a deletion in one gene from one parent, called a "hemizygous" deletion, can contribute to cancer.

28 May 2012

City of Hope receives CIRM grant to develop T cell-based immunotherapy against glioma

City of Hope was granted a $5,217,004 early translational research award by the California Institute for Regenerative Medicine (CIRM) to support the development of a T cell-based immunotherapy that re-directs a patient's own immune response against glioma stem cells.

28 May 2012

EMA CHMP adopts positive opinion for Pfizer’s axitinib to treat advanced renal cell carcinoma

Pfizer announced today that the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the marketing authorization of axitinib in the European Union (EU), for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of advanced kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

25 May 2012

Table-top solid-state laser system cuts brain tissue with unprecedented precision

Researchers from the Max Born Institute for Nonlinear Optics and Short Pulse Spectroscopy (MBI) were involved in the development of a table-top solid-state laser system that could cut brain tissue with unprecedented precision. The achievement is a result of an interdisciplinary EU project that involved partners from seven European countries.

25 May 2012

Thioridazine drug successfully kills human cancer stem cells

A team of scientists at McMaster University has discovered a drug, thioridazine, successfully kills cancer stem cells in the human while avoiding the toxic side-effects of conventional cancer treatments.

25 May 2012

Longer looks: When is a life too long?; The rising cost of children's health care

I will tell you, what I feel most intensely when I sit by my mother's bed is a crushing sense of guilt for keeping her alive. Who can accept such suffering-;who can so conscientiously facilitate it? ... In 1990, there were slightly more than 3 million Americans over the age of 85. Now there are almost 6 million. By 2050 there will be 19 million-;approaching 5 percent of the population.

25 May 2012

New compound can enhance apoptosis in cancer cells

The BCL-2 protein family plays a large role in determining whether cancer cells survive in response to therapy or undergo a form of cell death known as apoptosis.

25 May 2012

NYU Langone surgeons perform robotic-assisted partial nephrectomy in New York

A team of urological surgeons from NYU Langone Medical Center performed a robotic-assisted partial nephrectomy in New York and beamed the procedure from New York via high definition satellite to more than 400 participants attending the American Urological Association's (AUA) 2012 Annual Meeting in Atlanta earlier this week.

24 May 2012

Preliminary results from Celldex’s CDX-011 Phase 2b breast cancer study

Celldex Therapeutics, Inc. today announced preliminary results from the Company's randomized Phase 2b EMERGE study of CDX-011 (glembatumumab vedotin) antibody drug conjugate in patients with glycoprotein NMB (GPNMB) expressing, advanced, heavily pretreated breast cancer. Preliminary results suggest that CDX-011 induces impressive response rates compared to current, available therapies in patients with advanced, refractory breast cancers with high GPNMB expression.

24 May 2012

AVEO commences AV-203 Phase 1 study in advanced solid tumors

AVEO Oncology today announced the initiation of a Phase 1 study examining the safety and preliminary efficacy of AV-203 along with exploratory biomarkers in patients with advanced solid tumors.

23 May 2012

Study shows how chromosomal mutation likely contributes to early development of prostate cancer

Up to half of all prostate cancer cells have a chromosomal rearrangement that results in a new "fusion" gene and formation of its unique protein -- but no one has known how that alteration promotes cancer growth. Now, Weill Cornell Medical College researchers have found that in these cancer cells, the 3-D architecture of DNA, wrapped up in a little ball known as a chromatin, is warped in such a way that a switch has been thrown on thousands of genes, turning them on or off to promote abnormal, unchecked growth. Researchers also found that new chromosomal translocations form, further destabilizing the genome.

23 May 2012

New clinical trial to evaluate HSP90 inhibitor plus hormonal therapy for breast cancer

Pushed to the brink of survival, the hyper-driven cells of a cancerous tumor tap into an ancient system that has helped organisms cope with internal stresses and environmental challenges since life began. As an integral part of this system, heat shock protein 90 (HSP90) has been shown to help malignant cells accommodate the genetic changes and profound disturbances in normal biology that occur in cancers.

23 May 2012

Tumor News and Research

Oncos Therapeutics commences clinical study with oncolytic viruses

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Bioengineers develop first structure to grow small human blood vessels

Blocking Skp2 protein might inhibit glycolysis and treat breast cancer

Scientists show how hemizygous deletion can contribute to cancer

City of Hope receives CIRM grant to develop T cell-based immunotherapy against glioma

EMA CHMP adopts positive opinion for Pfizer’s axitinib to treat advanced renal cell carcinoma

Table-top solid-state laser system cuts brain tissue with unprecedented precision

Thioridazine drug successfully kills human cancer stem cells

Longer looks: When is a life too long?; The rising cost of children's health care

New compound can enhance apoptosis in cancer cells

NYU Langone surgeons perform robotic-assisted partial nephrectomy in New York

Preliminary results from Celldex’s CDX-011 Phase 2b breast cancer study

AVEO commences AV-203 Phase 1 study in advanced solid tumors

Study shows how chromosomal mutation likely contributes to early development of prostate cancer

New clinical trial to evaluate HSP90 inhibitor plus hormonal therapy for breast cancer

MRI provides early indication of breast tumor's response to pre-surgical chemotherapy

Folic acid fortification may reduce incidence of some childhood cancers

IntelliCell enters sponsored research agreement with ICERM

SDB may increase risk of cancer mortality

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News